Mereo Biopharma

Mereo Biopharma

Biopharmaceutical company focussed on the acquisition and rapid development of innovative medicines that have the potential to transform patient quality of life and improve human health. Learn more

Launch date
Employees
Market cap
CAD920m
Enterprise valuation
CAD809m (Public information from Sep 2024)
Company register number 09481161
London England (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
GBP2020202120222023202420252026
Revenues-36.5m-7.6m11.3m12.4m31.9m
% growth----49 %10 %157 %
EBITDA(37.5m)(20.3m)(42.1m)(18.1m)---
% EBITDA margin-(56 %)-(240 %)---
Profit(164m)12.7m(34.2m)(22.3m)(34.5m)(28.1m)(31.2m)
% profit margin-35 %-(295 %)(305 %)(227 %)(98 %)
EV / revenue-1.4x-28.0x39.8x42.0x16.5x
EV / EBITDA-4.6x-2.5x-0.7x-11.7x---
R&D budget15.9m23.6m25.0m13.2m---
R&D % of revenue-65 %-174 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound

$119m

Growth Equity VC
N/A

€14.9m

Valuation: €187m

-11.8x EV/LTM EBITDA

IPO
N/A

£14.8m

Post IPO Equity

£20.0m

Post IPO Equity
*

N/A

Post IPO Equity

$70.0m

Post IPO Equity
*

$50.0m

Post IPO Equity
Total FundingCAD162m

Recent News about Mereo Biopharma

Edit
More about Mereo Biopharmainfo icon
Edit

Mereo BioPharma is a biopharmaceutical company focused on developing innovative therapies for patients suffering from rare diseases. Operating in the healthcare and biotechnology market, Mereo BioPharma targets unmet medical needs by advancing a robust portfolio of clinical-stage products. The company's business model revolves around the research, development, and commercialization of novel treatments, primarily through strategic partnerships and collaborations with other pharmaceutical entities. Revenue is generated through licensing agreements, milestone payments, and eventual product sales. Mereo BioPharma serves a niche market of patients with rare and orphan diseases, aiming to provide better treatment options and improve their quality of life. The company is committed to scientific excellence and regulatory compliance, ensuring that its therapies meet the highest standards of safety and efficacy.

Keywords: biopharmaceutical, rare diseases, innovative therapies, clinical-stage products, healthcare, biotechnology, strategic partnerships, licensing agreements, orphan diseases, patient care.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.